Tata Memorial Hospital

Running trials

• Recruiting

  Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

  NCT06492486· Phase 2· Source

• Not yet recruiting

  Affordable Made-in-India Microspheres for Liver Cancer Therapy

  NCT07436988· Phase 1· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Source

• Recruiting

  Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)

  NCT07338526· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Source

• Active, not recruiting

  A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

  NCT07030517· Phase 4· Source

• Recruiting

  Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative

  NCT05774483· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Source

• Recruiting

  Tracing Brain Tumors Through Deep Time

  NCT06381531· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  Craniospinal Irradiation in Histone AlteRed Midline Glioma

  NCT06720727· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Source

• Active, not recruiting

  Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry

  NCT07354087· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Source

• Recruiting

  Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis

  NCT06036381· Source

• Active, not recruiting

  ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

  NCT05653063· Source

• Recruiting

  A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma

  NCT06016452· Phase 2· Source

• Recruiting

  Artificial Intelligence in CNS Radiation Oncology

  NCT06036394· Source

• Recruiting

  Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.

  NCT07400809· Source

• Recruiting

  Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients

  NCT07062263· Phase 3· Source

• Active, not recruiting

  SCRT in TNT With or Without Chlorophyllin

  NCT05856305· Phase 2· Source

• Recruiting

  Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

  NCT05857631· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Source

• Recruiting

  A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

  NCT05348876· Phase 4· Source

• Active, not recruiting

  A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

  NCT05732805· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Source

• Active, not recruiting

  To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer

  NCT05969314· Phase 1· Source

• Active, not recruiting

  A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT04819100· Phase 3· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Source

• Not yet recruiting

  Surgery Vs Chemoradiation for Oropharyngeal Cancer- A Phase II/III Integrated Design Randomized Control Trial

  NCT05144100· Phase 2/3· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· Phase 3· Source

• Recruiting

  Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers

  NCT04809324· Source

• Recruiting

  Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.

  NCT07179757· Source

• Recruiting

  Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India

  NCT07290972· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Source

• Recruiting

  Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

  NCT05236946· Phase 3· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Source

• Recruiting

  Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.

  NCT04474964· Source

• Recruiting

  Palliative Radiation for Advanced Cervical Cancer

  NCT03997110· Source

• Recruiting

  EORTC Metastatic Breast Cancer Module Development

  NCT07806266· Source

• Recruiting

  First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

  NCT04638790· Phase 3· Source

• Recruiting

  Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

  NCT05277844· Phase 2· Source

• Active, not recruiting

  Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children With Acute Lymphoblastic Leukemia

  NCT03974893· Source

• Active, not recruiting

  Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

  NCT03367702· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers10 recruiting
• Lung cancer5 recruiting
• Cervical cancer4 recruiting
• Head and neck cancer4 recruiting
• Colorectal cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Ovarian cancer3 recruiting
• Glioblastoma2 recruiting
• Metastatic breast cancer2 recruiting
• Endometrial cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men

  NCT04142385· Source

• Withdrawn

  Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

  NCT04142398· Source

• Completed

  Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience

  NCT05950737· Source

• Completed

  India HIV-CervCa Project

  NCT07167069· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· Phase 3· Source

• Completed

  Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

  NCT03934684· Phase 4· Source

• Completed

  Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

  NCT03564938· Phase 4· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

  NCT03573960· Phase 4· Source

• Completed

  Image Based Brachytherapy in Locally Advanced Cervical Cancers - a Randomized Controlled Trial

  NCT03005743· Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Phase 1/2· Source